UNSPSC 51334501: Cyprodenate

This classification denotes a cns stimulant with the molecular formula C13H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I44VIC13P8, chemically known as cyclohexanepropionic acid, 2-(dimethylamino)ethyl ester but generally known as cyprodenate, which bears US NIH Compound Identifier 71875. European Medicines Agency schedules Cyprodenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06874MIG.

UNSPSC 51334501 Cyprodenate is a Commodity code covering pharmaceutical active ingredients and precursor compounds used in the formulation of finished pharmaceuticals, but recent state and local opportunities show little activity directly tied to cyprodenate procurement. The code's nominal scope—a specific pharmaceutical intermediate or bulk chemical—does not align with the three recent solicitations in the dataset, which focus instead on finished naloxone products, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals distributed through established wholesaler networks. State and local buyers under related pharmaceutical codes pursue finished goods and supply-chain arrangements rather than raw chemical inputs or precursors.

The geographic spread of recent activity spans Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP cooperative purchasing). Issuing bodies include county health departments, state HHS commissions, and multistate cooperative purchasing alliances. Representative opportunities include Seminole County's IFB60459723LAS (IFB posted June 30, 2026, due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries); Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, exploring direct-to-manufacturer prescription programs); and Minnesota MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers). The cyprodenate code itself shows no relevant recent state and local procurement activity; vendors should focus on finished-pharmaceutical and supply-chain opportunities under higher-tier or sibling codes instead.